Key statistics
On Friday, RAPT Therapeutics Inc (RAPT:NMQ) closed at 57.72, -0.24% below its 52-week high of 57.86, set on Feb 04, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 57.82 |
|---|---|
| High | 57.82 |
| Low | 57.71 |
| Bid | 57.68 |
| Offer | 57.84 |
| Previous close | 57.82 |
| Average volume | 7.03m |
|---|---|
| Shares outstanding | 28.96m |
| Free float | 28.70m |
| P/E (TTM) | -- |
| Market cap | 1.67bn USD |
| EPS (TTM) | -11.08 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
- RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
- RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
- RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
- RAPT Therapeutics Announces Proposed Public Offering of Common Stock
- RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
- RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
- RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
- RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
More ▼
